Last reviewed · How we verify
Vemurafenib and Cobimetinib (vemurafenib-and-cobimetinib)
Vemurafenib and cobimetinib inhibit the BRAF and MEK enzymes, respectively, disrupting the MAPK signaling pathway to halt tumor growth in melanoma.
At a glance
| Generic name | vemurafenib-and-cobimetinib |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Mechanism of action
Vemurafenib targets the BRAF protein, which is often mutated in melanoma, while cobimetinib blocks MEK, another key player in the same pathway. Together, they effectively stop cancer cells from growing and spreading.
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Anaemia
- Rash
- Arthralgia
- Decreased appetite
- Vomiting
- Pyrexia
- Constipation
- Abdominal pain
- Pruritus
Key clinical trials
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (PHASE2)
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (PHASE3)
- Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vemurafenib and Cobimetinib CI brief — competitive landscape report
- Vemurafenib and Cobimetinib updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI